MICROBIO was founded in 2000, and over a decade of growth the company continues its unwaveringly dedication to “NOVEL THERAPEUTICS DEVELOPMENT and HUMAN LIFESTYLE IMPROVEMENT.” Microbio Group is now comprised of MICROBIO, ONENESS, FOUNTAIN BIOPHARMA, MICROBIO SHANGHAI, MICROSOY, COTTON FIELD and DIAMOND BIOFUND.
The Group’s approach to innovative and responsible drug development has led to two successful new drug approvals by the Taiwanese Food and Drug Administration (TFDA), ChemoYoung and Herbiron. Currently, Microbio Group has a handful of promising new drugs in clinical development (ON101 and MB-6) and more than a dozen potential candidates in the pipeline, which include botanical drugs, new chemical entities, monoclonal antibodies and glyco-molecules. The Microbio Group operates in concert with its subsidiary companies to maximize collaborative potential and develop innovative drugs in the field of oncology, immune, metabolic and infectious diseases. Equipped with an outstanding research team and business infrastructure, along with genuine drive to improve human health, Microbio Group is making adamant strides in the global arena of biotechnology.
MICROBIO utilizes its proprietary fermentation platform to develop its first FDA-approved new drug, ChemoYoung. It represents a first-ever oral drug indicated to fatigue and appetite loss associated with chemotherapy. And in March 2013, Herbiron was also approved for indication to improve primary dysmenorrhea and iron-deficiency anemia in women. Additional candidates in clinical development include MB-6 as an adjuvant to colorectal cancer therapy and MB-110. MB-110 is a novel NS5A inhibitor against Hepatitis C virus, and preclinical investigation shows high selectivity and efficacy against Asian HCV genotypes. In addition, MICROBIO has several preclinical projects underway, collaborating with prestigious academic and national research groups to develop new drugs with scientific and technical caliber fit for global platform.

ONENESS BIOTECH is a botanical drug-based specialty pharma, its discovery platform successfully identified ON101 as a potent wound healing agent, ON101 is currently under Phase III clinical trial to treat diabetic foot ulceration, and trial site includes Taiwan and Hong Kong, with Greater China as target market. Another Oneness Biotech drug candidate OB318 is derived from indigenous medicinal plant Antrodia cinnamomea and exhibit strong anti-tumor and anti-angiogenesis efficacy in inhibiting hepatic, breast and prostate cancer cells in preclinical models, and IND application is scheduled for 2014-Q3. In addition to drug pipeline, Oneness Biotech is also active in health-related product development. For example, “Antrodia cinnamomea mycelia capsule” is a health supplement with liver-protective effect and gained benefit and quality recognition from the Taiwanese Ministry of Health and Welfare (MOHW health food identification number A00244 and Symbol of National Quality (SNQ) number A01200).
FOUNTAIN BIOPHARA specializes in the development of monoclonal antibody new drugs, its proprietary phage display library combined with multi-functional screening platform has successfully identified new drug candidates, such as FB704A, a novel anti-IL-6 monoclonal antibody with superior binding and efficacy than known competitors and it is expected to submit for an US IND in 2016. Fountain Biopharma is currently co-developing the next-generation anti-IgE monoclonal antibody (FB825) with Academia Sinica, with the talent and expertise that discovered and developed the blockbuster anti-IgE monoclonal drug, Xolair. FB825 has successfully secured two US patent and the US IND application is scheduled in 2014-Q3. In addition, the FB811 development represents the world’s first homogenously glycosylated monoclonal antibody, a project that Fountain Biopharma works closely with CHO Pharma, to accelerate the clinical development. Fountain Biopharma strives to cultivate an outstanding R&D base in Taiwan with the vision of striding into global drug market. Fountain Biopharma welcomes international collaboration and licensing opportunities to maximize the R&D value and market potential.
The Microbio Group is a Taiwan-based Drug Development Enterprise that prizes itself in its innovative and responsible drug development. Originated and cultivated in Taiwan with close connection to the academic and industry, built up the strength to be an active player in the global arena. Microbio envisions provision of novel solutions for unmet medical needs, create shareholder value, and commit to improve human lives.